Literature DB >> 18438722

Immunohistochemical examination of gastrin, gastrin precursors, and gastrin/CCK-2 receptor in human esophageal squamous cell carcinomas.

Aping Yuan1, Jinzhong Liu, Yiqing Liu, Tone Bjørnsen, Andrea Varro, Guanglin Cui.   

Abstract

A promoting effect of gastrin on stimulating Barrett's oesophagus proliferation has been demonstrated, but whether it plays a regulating role for esophageal squamous cell carcinoma (ESCC) to date has not been fully investigated. The aim of this study is to examine the expressions of gastrin, gastrin precursors and gastrin/CCK-2 receptor in ESCC. Tissue specimen sections from 38 patients with ESSC obtained from a high incidence area of north China were assessed using immunohistochemistry for amidated gastrin, gastrin precursors (progastrin and glycine-extended gastrin) and gastrin/CCK-2 receptors. Their clinical histopathological significance was also analyzed. Of 38 ESCC, the immunoreactivities of gastrin, glycine-extended gastrin and progastrin were observed in 13.2% (5/38), 7.9% (3/38) and 23.68% (9/38) cases. The expression of progastrin was obviously higher than other gastrins, though not significantly (P > 0.05). In positive cases for gastrin or glycine-extended gastrin, the scores of positive tumor cell numbers were at a lower density (<10/abundant-distributed field). However, the scores of progastrin positive tumor cell density in five of nine positive cases were over 10/abundant-distributed field. The immunoreactivity of gastrin/CCK-2 receptor was also observed in 15.8% (6/38) ESCC cases. There was not significant correlation regarding immunohistochemical results with known histomorphological parameters i.e. gender, tumor location and TNM stages. Based on our current results, ESCC tumor cells could be a possible cellular source of gastrin precursors, which has been postulated to play a role in regulating the growth in some human tumor cells.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18438722     DOI: 10.1007/s12253-008-9047-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  47 in total

1.  Expression of progastrin-derived peptides and gastrin receptors in a panel of gastrointestinal carcinoma cell lines.

Authors:  A Kelly; F Hollande; A Shulkes; G S Baldwin
Journal:  J Gastroenterol Hepatol       Date:  1998-02       Impact factor: 4.029

2.  Gastrin stimulates receptor-mediated proliferation of human esophageal adenocarcinoma cells.

Authors:  T Carlton Moore; Lisa I Jepeal; Michael O Boylan; Satish K Singh; Nick Boyd; David G Beer; Albert J Chang; M Michael Wolfe
Journal:  Regul Pept       Date:  2004-08-15

3.  Insulin-like growth factor-I receptor as a marker for prognosis and a therapeutic target in human esophageal squamous cell carcinoma.

Authors:  Arisa Imsumran; Yasushi Adachi; Hiroyuki Yamamoto; Rong Li; Yu Wang; Yongfen Min; Wenhua Piao; Katsuhiko Nosho; Yoshiaki Arimura; Yasuhisa Shinomura; Masao Hosokawa; Choon-Taek Lee; David P Carbone; Kohzoh Imai
Journal:  Carcinogenesis       Date:  2006-12-20       Impact factor: 4.944

4.  Glycine-extended gastrin stimulates proliferation and inhibits apoptosis in colon cancer cells via cyclo-oxygenase-independent pathways.

Authors:  Olorunseun Olatunji Ogunwobi; Ian L P Beales
Journal:  Regul Pept       Date:  2005-09-19

5.  Closing the gastrin loop in pancreatic carcinoma: coexpression of gastrin and its receptor in solid human pancreatic adenocarcinoma.

Authors:  J P Goetze; F C Nielsen; F Burcharth; J F Rehfeld
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

6.  The biological and therapeutic importance of gastrin gene expression in pancreatic adenocarcinomas.

Authors:  Joseph C Harris; Andrew D Gilliam; Andrew J McKenzie; Sean A Evans; Anna M Grabowska; Philip A Clarke; Daniel F McWilliams; Sue A Watson
Journal:  Cancer Res       Date:  2004-08-15       Impact factor: 12.701

7.  Evidence for autocrine growth stimulation of cultured colon tumor cells by a gastrin/cholecystokinin-like peptide.

Authors:  N M Hoosein; P A Kiener; R C Curry; M G Brattain
Journal:  Exp Cell Res       Date:  1990-01       Impact factor: 3.905

8.  Glycine-extended gastrin promotes the growth of lung cancer.

Authors:  Theodore J Koh; John K Field; Andrea Varro; Triantafillos Liloglou; Pat Fielding; Guanglin Cui; JeanMarie Houghton; Graham J Dockray; Timothy C Wang
Journal:  Cancer Res       Date:  2004-01-01       Impact factor: 12.701

Review 9.  Gastrins, cholecystokinins and gastrointestinal cancer.

Authors:  Ahmad Aly; Arthur Shulkes; Graham S Baldwin
Journal:  Biochim Biophys Acta       Date:  2004-07-06

Review 10.  The role of gastrin and cholecystokinin in normal and neoplastic gastrointestinal growth.

Authors:  G S Baldwin
Journal:  J Gastroenterol Hepatol       Date:  1995 Mar-Apr       Impact factor: 4.029

View more
  5 in total

1.  Cellular changes in the tumor microenvironment of human esophageal squamous cell carcinomas.

Authors:  Jinzhong Liu; Zhenfeng Li; Jing Cui; Gang Xu; Guanglin Cui
Journal:  Tumour Biol       Date:  2011-12-02

2.  Tumor-Associated Fibroblasts and Microvessels Contribute to the Expression of Immunosuppressive Factor Indoleamine 2, 3-Dioxygenase in Human Esophageal Cancers.

Authors:  Guanglin Cui; Can Li; Gang Xu; Zhenglu Sun; Li Zhu; Zhengfen Li; Wei Zheng; Junling Li; Aping Yuan
Journal:  Pathol Oncol Res       Date:  2017-05-03       Impact factor: 3.201

3.  Localization of indoleamine 2,3-dioxygenase in human esophageal squamous cell carcinomas.

Authors:  Jinzhong Liu; Gaofeng Lu; Fuai Tang; Yiqing Liu; Guanglin Cui
Journal:  Virchows Arch       Date:  2009-10-21       Impact factor: 4.064

Review 4.  Novel roles of gastrin.

Authors:  Rod Dimaline; Andrea Varro
Journal:  J Physiol       Date:  2014-03-24       Impact factor: 5.182

5.  Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue.

Authors:  Jyoti Roy; Karson S Putt; Domenico Coppola; Marino E Leon; Farah K Khalil; Barbara A Centeno; Noel Clark; Valerie E Stark; David L Morse; Philip S Low
Journal:  Oncotarget       Date:  2016-03-22
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.